NEW YORK (GenomeWeb) – GenMark Diagnostics announced after the close of the market on Tuesday that it has applied to the US Food and Drug Administration for clearance of its ePlex Blood Culture Identification Gram-Negative (BCID-GN) and ePlex Blood Culture Identification Fungal Pathogen (BCID-FP) panels.

As a result, the firm has now completed submissions for all three of its ePlex molecular multiplex panels designed for the diagnosis and management of bloodstream infections that can lead to sepsis. The panels are being developed on GenMark's ePlex sample-to-answer system.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.